J. Anderton

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Paul D. Smith, R. Wilkinson, B. Barlaam, 2010, Clinical Cancer Research.

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

B. Davies, R. Wilkinson, G. Speake, 2009, Anti-cancer drugs.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Simon J. Dovedi, D. Greenawalt, Dennis Wang, 2016, Cancer Immunology Research.

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

B. Barlaam, R. Bradbury, P. Ballard, 2013, ACS medicinal chemistry letters.

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

M. Albertella, Z. Cooper, R. Christie, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

D. Greenawalt, Dennis Wang, R. Sainson, 2016, Cancer Immunology Research.

MHC class II antigen expression is not induced on murine epidermal keratinocytes by interferon-gamma alone or in combination with tumour necrosis factor-alpha.

H. Yeoman, J. Anderton, M. Stanley, 1989, Immunology.